Tesla, Southwest, Apple, AMC and more

0
244
Tesla, Southwest, Apple, AMC and more

A sign hangs in front of an AMC theater on January 27, 2021 in Chicago, Illinois. AMC Entertainment shares have more than quadrupled today as investors continue their buying spree on deeply shorted stocks.

Scott Olson | Getty Images

Check out the companies making headlines in midday trading.

Tesla – Electric vehicle stock is up more than 3% after selling off during 10 of the past 11 trading sessions. Baird also lowered its share price target to $252 from $316 per share.

Southwest Airlines – Shares of the airline fell 2.5% as it continues to operate a reduced flight schedule. Southwest canceled 60% of its flights scheduled for Wednesday, while rival airlines capped fares to help stranded travelers.

AMC entertainment – Shares of AMC Entertainment fell about 3% a day after CEO Adam Aron tweeted that he had asked the company’s board to freeze his salaries for 2023 and urged other executives to forego raises.

generic — The gear maker gained 5% after Janney Montgomery Scott’s purchase initiation. The company gave the stock a price target of $160, up 75.5% from Tuesday’s close.

no — Shares of the electric car maker fell 2%. It builds on Tuesday’s 8% decline, which came after it announced fourth-quarter production cuts due to Covid outbreaks.

Energy Stocks – A number of energy companies tumbled in tandem with falling oil and natural gas prices. EQT down more than 6% WHAT 3.6% lost and coterra 3.5% lost. These three names were among the biggest losers in the S&P 500 during midday trading.

Maxeon — Shares fell 8% after the solar company announced that Bill Mulligan would become its new CEO. Previously, he was Chief Operating Officer at Sila Nanotechnologies.

Apple — Shares of the tech giant fell 1.5%. The stock has fallen for the past three days and hit a fresh 52-week low on Wednesday.

IDEAYA Life Sciences — IDEAYA gained nearly 5% after beginning an overweight position in Capital One Securities. The company gave the stock a price target of $29, up 75.4% from Tuesday’s close.

Kala Pharma — The biopharmaceutical company rose more than 200% after the Food and Drug Administration accepted a new investigational application for a new drug for its potential treatment of a persistent corneal epithelial defect.

– CNBC’s Samantha Subin, Tanaya Macheel and Sarah Min contributed coverage.